Hyperuricemia in patients with stable coronary artery disease and arterial hypertension and percutaneous coronary interventions
- Authors: Mironova O.l.1, Fomin V.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 22, No 12 (2020)
- Pages: 20-22
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95351
- DOI: https://doi.org/10.26442/20751753.2020.12.200555
- ID: 95351
Cite item
Full Text
Abstract
Aim. To assess the influence of hyperuricemia on the risk of contrast-induced acute kidney injury (CI-AKI) in patients with stable coronary artery disease (CAD) and arterial hypertension. Materials and methods. Patients receiving optimal medical therapy and with indications for coronary angiography and possible coronary angioplasty, with stable CAD and arterial hypertension were included in the study. We conducted an observational open prospective cohort study, that was registered in clinicaltrials.gov with ID NCT04014153. Results. We included 1023 patients with chronic CAD. 863 had arterial hypertension. Hyperuricemia was diagnosed in 31 patients, 832 had normal levels of uric acid on admission. Contrast-induced acute kidney injury developed in 2 (6.5%) patients suffering from hyperuricemia. In patients with stable CAD, AH and no hyperuricemia the rate of CI-AKI was 107 (12.9%) patients. The difference between groups was not statistically significant (95% CI -0.056-0.183, p=0.292). We built a multiple linear regression model that included age, weight, female gender, heart failure, diabetes mellitus, kidney diseases in past medical history, proteinuria, anemia, baseline glomerular filtration rate, contrast volume and difference between baseline creatinine and creatinine after contrast administration. No risk factor showed any statistical significance in the model. Conclusion. Contrast-induced acute kidney injury developed in 2 (6.5%) patients suffering from hyperuricemia. The rate of CI-AKI in patients without hyperuricemia was twice higher but the results were not statistically significant. Among the risk factors included in the multiple linear regression model none was statistically significant.
Full Text
##article.viewOnOriginalSite##About the authors
Olga lu. Mironova
Sechenov First Moscow State Medical University (Sechenov University)
Email: mironova_o_yu@staff.sechenov.ru
канд. мед. наук, доц. каф. факультетской терапии Moscow, Russia
Viktor V. Fomin
Sechenov First Moscow State Medical University (Sechenov University)чл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе и дополнительному профессиональному образованию Moscow, Russia
References
- Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21.
- Чазова И.Е., Шестакова М.В., Жернакова Ю.В. и др. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020; 17 (1): 7-45.
- Ostermann M, Bellomo R, Burdmann EA et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2020; 98 (2): 294-309.
- Миронова О.Ю. Индуцированная контрастными веществами нефропатия. Терапевтический архив. 2013; 85 (6): 90-5.
- KDIGO Working Group. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;(1): 124-38. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO AKI Guideline.pdf
- Williams B, Mancia G, De Backer G et al. 2018 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2018; 25 (6): 1105-87.
- Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37 (27): 2129-200m.
- Dedov II, Shestakova MV, Mayorov AY et al. Standards of specialized diabetes care. Diabetes Mellit 2017; 20 (1S): 1-112.
- Khanna D, Fitzegarld J, Khanna P et al. American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res 2012; 64 (10): 1431-46. http://www.ncbi.nlm.nih.gov/ pubmed/3683400%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC368044
- Алиментарные анемии. Доклад научной группы ВОЗ. 1970.
- Kim S-K. Interrelationship of Uric Acid, Gout, and Metabolic Syndrome: Focus on Hypertension, Cardiovascular Disease, and Insulin Resistance. J Rheum Dis 2018; 25 (1): 19.
- Ichida K, Matsuo H, Takada T et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012; 3: 764-7. doi: 10.1038/ncomms1756
- Abeles AM, Pillinger MH. Gout and cardiovascular disease: crystallized confusion. Curr Opin Rheumatol 2019; 31 (2): 118-24.